We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Large Scale Clinical Chemistry and Immunochemistry Analyzer Launched in UK

By LabMedica International staff writers
Posted on 16 Nov 2009
A modular clinical chemistry and immunochemistry analyzer will provide the UK with large scale, high speed in vitro diagnostic (IVD) testing.

With a peak throughput of up to 8,400 tests per hour and 270 reagents on board, the cobas 8000 modular analyzer series merges the latest serum-work area technology with new process innovations. More...
It incorporates many new design elements such as module sample buffers and independent transport and processing lines for improved sample management. The convenient clinical chemistry reagent cassette with ready to-use reagents provides long on-board stability, and varying cassette sizes optimized for workflow and cost management.

Produced by Roche Diagnostics UK (Burgess Hill, UK), the cobas 8000 modular analyzer3 series is the newest member of the Roche cobas modular platform and combines clinical chemistry and immunochemistry testing. It is designed to enable high volume laboratories to deliver reliable results with optimal workflow and cost efficiency.

Tests run on the new platform provide the physician with important clinical information in a wide range of medical areas such as infectious and cardiac disease, bone disorders, and cancer. It also includes a range of novel biomarkers for maternal care and rheumatoid arthritis.

Roche Diagnostics has launched the cobas 8000 in the United Kingdom. This "hi-spec" instrument fills will provide the U.K. with large scale, high speed in vitro diagnostic (IVD) testing. This newest addition to the cobas family of integrated analyzers will allow extremely fast and efficient testing procedures and will significantly reduce sample turn-around.

"At Roche we are committed to creating true medical value through delivering leading edge diagnostic tests and technologies," said Ian Parfrement, director of hospital IVD at Roche. "The cobas 8000 modular analyzer series is a landmark technology which is uniquely designed to address the needs of high volume laboratories."

"The NHS demands greater flexibility for pathology testing to meet the overall aim of delivering improved patient care whilst responding to financial pressures," continued Parfrement. "With the introduction of the cobas 8000 as part of the overall Roche modular analyzer series, healthcare professionals are able to get the same consistent and highly accurate results no matter the testing environment."

The first configuration of cobas 8000 modular analyzer series to be launched is the high-speed clinical chemistry cobas c 701 module with up to 2000 tests per hour. In the coming months additional clinical chemistry and immunoassay modules will be introduced resulting in more than 38 scalable solutions which can be tailored to suit laboratories' current and future needs.

Related Links:
Roche Diagnostics UK



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.